TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

R

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: US

Quick snapshot

R

ST13

US500000079396229

Class

5, 42

Filing

79396229

Registration

7943034

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

33

Latest update

04/25/2026

Classification

Registered

Trademark type

Combined

Nice classes

5, 42

Filing date

04/12/2024

Registration date

09/16/2025

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

09/16/2025

Last transaction

04/25/2026

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Drawing code

3

Owner type

99

Owner location

BE

Examiner

SMITH, CAROLINE P

Law office

M10

Current location

FILE REPOSITORY (FRANCONIA)

Mark description

The mark consists of a stick figure man with the body shown in dark blue and an orange circle as the head.

Holders and representatives

Holders

Rejuvenate Biomed NV

Representatives

Cheryl L. Burbach Erise IP, P.A.

Technical classification

Nice Classes

Class 5Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Medical, biological, and pharmaceutical preparations for the treatment of viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; veterinary preparations for pets, cattle, livestock, for the treatment of viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical, biological, and pharmaceutical preparations for preventing and treating viral, bacterial, and yeast infections; veterinary preparations for pets, cattle, livestock, for preventing and treating viral, bacterial, and yeast infections; medical, biological, and pharmaceutical preparations for preventing and treating cancer, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; veterinary preparations for pets, cattle, livestock for preventing and treating cancer, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccines; sanitary preparations for medical purposes; dietary supplements and dietetic preparations adapted for medical purposes; dietetic foods adapted for medical use; diagnostic preparations for medical purposes; diagnostic chemical reagents for medical use; clinical medical reagents

Class 42

Biological research; clinical research in the field of age-related diseases and cancer; medical research; research and development services in the field of pharmaceutical preparations; pharmaceutical products development; pharmaceutical product evaluation; research and development in the field of microorganisms and cells; research on the subject of pharmaceuticals; testing of pharmaceuticals; laboratory research services relating to pharmaceutical product development; development of gene-based medicines; drug discovery services; scientific research in the nature of conducting clinical trials for others relating to pharmaceutical products; scientific laboratory services; laboratory research services relating to pharmaceuticals; scientific risk assessment being consultation in the field of health risk assessment, namely, prediction and assessment of health risks to public and private agencies, facilities, individuals and locations following an accidental or terrorist caused release of chemical, biological, radiological or nuclear materials; consulting services in the field of pharmaceutical research; testing of pharmaceuticals being services for assessing the efficiency of pharmaceuticals; pharmaceutical toxicity testing for research purposes; pharmaceutical toxicity analysis services for scientific research purposes; computer services, namely, remote management of the information technology (IT) systems of others for the pharmaceutical and healthcare industries; conducting early evaluations in the field of new pharmaceuticals; providing information about scientific research, namely, the results of clinical trials for pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; chemical research and analysis services; medical and pharmacological research services; scientific services, namely, scientific research in the field of genetics; scientific research for medical purposes in the field of age-related diseases and cancer; medical and scientific research, namely, conducting clinical trials for others; scientific research in the field of genetics; genetic mapping for scientific purposes; DNA screening for scientific research purposes; providing scientific research information in the field of pharmaceuticals for the treatment of medical disorders; technical research in the field of pharmaceutical studies; veterinary research; design and development of computer software relating to the medical field; design and development of computer software relating to healthcare; computer programming in the medical field; scientific computer programming services; providing temporary use of non-downloadable software for capturing, storing, processing, evaluating and reproducing medical and pharmaceutical data; providing temporary use of on-line non-downloadable computer programs on data networks using artificial intelligence (AI) for use in the life sciences research field, pharmaceutical research, medical research, drug discovery and development; platform as a service (PAAS) featuring computer software platforms using artificial intelligence (AI) for use in the life sciences research field, pharmaceutical research, medical research, drug discovery and development; software as a service (SaaS) services featuring software for capturing, storing, processing, evaluating and reproducing medical and pharmaceutical data in the life sciences research field, pharmaceutical research, medical research, drug discovery and development; software as a service (SaaS) featuring software using artificial intelligence (AI) for capturing, storing, processing, evaluating and reproducing medical and pharmaceutical data in the life sciences research field, pharmaceutical research, medical research, drug discovery and development; software as a service (SaaS) featuring software using artificial intelligence (AI) for analysis of self-assessment of illnesses; software as a service (SaaS) featuring software using artificial intelligence (AI) for machine learning in the field of healthcare; software as a service (SaaS) featuring health monitoring software; software as a service (SaaS) featuring software for analyzing biological genetic data; technology consultation in the field of artificial intelligence (AI); research in the field of artificial intelligence (AI)

Publications

History of USPTO decisions and trademark events.

33 publications found

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

04/23/2026

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

04/23/2026

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

04/23/2026

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

04/23/2026

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

04/23/2026

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

04/16/2026

FICS

FINAL DISPOSITION NOTICE SENT TO IB

03/28/2026

FIMP

FINAL DISPOSITION PROCESSED

03/27/2026

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

12/16/2025

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

11/22/2025

NREP

NEW REPRESENTATIVE AT IB RECEIVED

11/14/2025

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

10/22/2025

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

10/22/2025

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

09/16/2025

R.PR

REGISTERED-PRINCIPAL REGISTER

09/16/2025

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

07/29/2025

PUBO

PUBLISHED FOR OPPOSITION

07/29/2025

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

07/23/2025

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

06/20/2025

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

05/01/2025

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

05/01/2025

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

05/01/2025

NREP

NEW REPRESENTATIVE AT IB RECEIVED

03/28/2025

RFNT

REFUSAL PROCESSED BY IB

11/23/2024

ADCH

CHANGE OF NAME/ADDRESS REC'D FROM IB

11/08/2024

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

11/05/2024

RFRR

REFUSAL PROCESSED BY MPU

11/05/2024

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

10/30/2024

CNRT

NON-FINAL ACTION WRITTEN

10/29/2024

DOCK

ASSIGNED TO EXAMINER

10/25/2024

MAFR

APPLICATION FILING RECEIPT MAILED

06/03/2024

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

06/03/2024

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

05/23/2024

Continuous trademark protection

Get notified about every new filing that threatens R or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.